Glossary

Cell-Free DNA (cfDNA)

Short fragments of DNA released into the bloodstream through cell death and secretion, serving as the primary analyte in liquid biopsy for non-invasive cancer detection and monitoring.

Get in touch Learn more

Stylish WeWork-like workspace with hot desks and document wall, professional searching through enterprise knowledge base on a mounted ultrawide display, warm industrial pendants overhead.

LIQUID BIOPSY ANALYTE

What is Cell-Free DNA (cfDNA)?

Cell-free DNA (cfDNA) refers to short, degraded fragments of DNA freely circulating in the bloodstream and other bodily fluids, released primarily through apoptosis, necrosis, and active cellular secretion.

Cell-free DNA (cfDNA) is the collective term for extracellular DNA fragments found in circulation, typically ranging from 120 to 220 base pairs in length—corresponding to the DNA wrapped around a single nucleosome. These fragments are shed into the bloodstream by both normal and diseased cells during routine cell turnover, providing a real-time, systemic snapshot of an individual's genomic and epigenomic state without requiring an invasive tissue biopsy.

In oncology, cfDNA serves as the foundational analyte for liquid biopsy, where the subset originating from tumor cells—known as circulating tumor DNA (ctDNA)—is interrogated for somatic mutations, copy number alterations, and methylation patterns. Machine learning algorithms are critical for analyzing cfDNA fragmentomics features, such as fragment length distributions and end motif frequencies, to infer the tissue of origin and distinguish true cancer signals from background noise caused by clonal hematopoiesis.

ANALYTE PROPERTIES

Key Characteristics of cfDNA

Understanding the biophysical and biological properties of cell-free DNA is essential for designing robust liquid biopsy assays and interpreting sequencing data.

Fragmentation Profile

cfDNA is highly fragmented, with a predominant peak at ~166 base pairs (bp) corresponding to DNA wrapped around a single nucleosome, plus a linker. This nucleosome footprint is a non-random biological signal. Shorter fragments (<150 bp) are often enriched for tumor-derived DNA, making fragment size selection a critical pre-analytical step. Fragmentomics leverages these patterns to infer tissue of origin and gene regulation.

~166 bp

Dominant Peak Length

10 bp

Periodicity Ladder

Biological Origin & Release

cfDNA enters the circulation through a combination of apoptosis (programmed cell death), necrosis (uncontrolled cell death), and active secretion. In healthy individuals, the majority originates from hematopoietic cells. In cancer patients, a variable fraction—Circulating Tumor DNA (ctDNA)—is shed directly from the tumor microenvironment, carrying somatic mutations.

< 0.01%

ctDNA Fraction at Early Stages

Rapid Clearance Dynamics

The half-life of cfDNA in the bloodstream is extremely short, ranging from 16 minutes to 2.5 hours. Clearance is mediated primarily by nuclease degradation in the blood and uptake by the liver and kidneys. This rapid turnover means a liquid biopsy provides a real-time snapshot of disease burden, but it also requires strict pre-analytical handling to prevent ex vivo degradation.

16 min - 2.5 hrs

Circulating Half-Life

Low Concentration & Rarity

cfDNA is a scarce analyte. In a typical 10 mL blood draw, only ~10 ng/mL of total cfDNA is recovered from plasma. The ctDNA fraction can be vanishingly small, often < 0.1% of total cfDNA in early-stage disease. This extreme dilution necessitates ultra-sensitive detection methods like Unique Molecular Identifiers (UMIs) and Duplex Sequencing to suppress background errors.

~10 ng/mL

Typical Plasma Concentration

Epigenetic Information Content

Beyond genetic sequence, cfDNA preserves epigenetic marks, most notably DNA methylation patterns. Since methylation is highly tissue-specific, the methylation pattern of cfDNA fragments acts as a barcode to identify the cell of origin. This enables multi-cancer early detection tests that localize the tumor's anatomical site without prior clinical indication.

5-mC

Key Epigenetic Modification

Pre-Analytical Instability

cfDNA is chemically unstable ex vivo. Delays in plasma separation lead to leukocyte lysis, contaminating the sample with high-molecular-weight genomic DNA and diluting the true ctDNA signal. Standard protocols require processing within 4-6 hours using specialized cell-stabilization tubes. Hemolysis and repeated freeze-thaw cycles further degrade the analyte.

< 4-6 hrs

Time to Plasma Separation

LIQUID BIOPSY ANALYTE COMPARISON

cfDNA vs. ctDNA: Critical Distinctions

Key biological, technical, and clinical distinctions between total cell-free DNA and the tumor-derived fraction.

Feature	Cell-Free DNA (cfDNA)	Circulating Tumor DNA (ctDNA)	Germline cfDNA
Definition	All extracellular DNA in circulation	Fraction of cfDNA shed by tumor cells	cfDNA from normal, non-malignant cells
Source	Apoptosis, necrosis, active secretion	Tumor apoptosis, necrosis, CTC lysis	Normal cell turnover, hematopoietic cells
Carries Somatic Mutations
Typical Fraction in Plasma	100% (total pool)	0.01% to >50% of cfDNA	Majority of cfDNA in healthy individuals
Fragment Length Peak	~166 bp (nucleosomal)	~134-144 bp (shorter)	~166 bp
Clinical Utility	Total DNA quantification, fragmentomics	Genotyping, MRD, treatment response	Clonal hematopoiesis filtering, normal control
Variant Allele Frequency Range	N/A	0.01% to 50%	50% or 100% for germline variants
Half-Life in Circulation	16 minutes to 2.5 hours	16 minutes to 2.5 hours	16 minutes to 2.5 hours

Enabling Efficiency, Speed & Accuracy

Intelligent Analysis, Decision & Execution

We build AI systems for teams that need search across company data, workflow automation across tools, or AI features inside products and internal software.

Talk to Us

Search across company data

Give teams answers from docs, tickets, runbooks, and product data with sources and permissions.

Useful when people spend too long searching or get different answers from different systems.

Enterprise searchRAGPermissions

Automate internal workflows

Use AI to route work, draft outputs, trigger actions, and keep approvals and logs in place.

Useful when repetitive work moves across multiple tools and teams.

AI agentsWorkflow automationGovernance

Add AI to products and internal tools

Build assistants, guided actions, or decision support into the software your team or customers already use.

Useful when AI needs to be part of the product, not a separate tool.

AI integrationDecision supportModel routing

LIQUID BIOPSY BASICS

Frequently Asked Questions

Clear, technically precise answers to the most common questions about cell-free DNA biology, analysis, and clinical utility.

Cell-free DNA (cfDNA) refers to short, fragmented double-stranded DNA molecules freely circulating in the bloodstream and other bodily fluids, released primarily through apoptosis, necrosis, and active cellular secretion. In healthy individuals, the majority of cfDNA originates from hematopoietic cells of the bone marrow, with smaller contributions from other tissues. The fragments are typically 166 base pairs in length, corresponding to the DNA wrapped around a single nucleosome core plus a linker region, reflecting the enzymatic cleavage pattern of caspase-activated DNase during programmed cell death. The half-life of cfDNA in circulation is remarkably short, ranging from 16 minutes to 2.5 hours, meaning it provides a real-time snapshot of ongoing cell turnover. Rapid clearance occurs via nuclease degradation in the blood, renal filtration, and uptake by the liver and spleen. In cancer patients, a variable fraction of this cfDNA—known as circulating tumor DNA (ctDNA)—is shed directly from tumor cells, carrying the somatic mutations, copy number alterations, and epigenetic signatures of the malignancy.

LIQUID BIOPSY ANALYTICS

Related Terms

Core concepts in the computational analysis of cell-free DNA for non-invasive cancer detection and monitoring.

Circulating Tumor DNA (ctDNA)

The tumor-derived fraction of cell-free DNA carrying somatic mutations. ctDNA is distinguished from normal cfDNA by the presence of driver mutations, copy number alterations, and methylation patterns specific to the malignancy. Its concentration correlates with tumor burden and is used for:

Minimal residual disease (MRD) detection
Treatment response monitoring
Acquired resistance mutation tracking

< 0.01%

Typical ctDNA fraction in early-stage cancer

Fragmentomics

The study of cfDNA fragmentation patterns to infer tissue of origin and epigenetic state. Key features include:

Fragment length: ctDNA tends to be shorter (~134 bp) than non-tumor cfDNA (~167 bp)
End motifs: The 4-base sequence at fragment termini reflects nuclease preferences
Nucleosome footprints: Coverage peaks at transcription start sites reveal active regulatory regions
Jagged ends: Single-stranded overhangs indicate enzymatic cleavage mechanisms

Unique Molecular Identifier (UMI)

A random nucleotide barcode ligated to individual DNA molecules before PCR amplification. UMIs enable:

Computational deduplication: Reads sharing the same UMI and genomic coordinates are collapsed into a consensus
Absolute quantification: Counting unique UMIs reveals the original number of template molecules
Error suppression: Random polymerase errors are averaged out during consensus building, achieving error rates below 1 in 10,000

Variant Allele Frequency (VAF)

The percentage of sequencing reads at a given genomic locus that carry a variant allele. In liquid biopsy, VAF is a critical metric for:

Estimating the proportion of ctDNA in total cfDNA
Distinguishing clonal (high VAF) from subclonal (low VAF) mutations
Tracking dynamic changes in tumor burden during therapy
Filtering clonal hematopoiesis variants, which often present at stable, low VAF

Methylation Pattern Analysis

The distribution of 5-methylcytosine at CpG dinucleotides serves as a tissue-specific epigenetic fingerprint. Computational deconvolution of methylation patterns enables:

Cell-of-origin determination: Identifying whether cfDNA originated from liver, lung, colon, or other tissues
Multi-cancer early detection: Pan-cancer screening without prior knowledge of the primary site
Immune cell deconvolution: Estimating the contribution of leukocyte cfDNA to total circulating DNA

Clonal Hematopoiesis Filtering

A computational strategy to exclude somatic variants originating from age-related clonal expansions in hematopoietic stem cells rather than from a solid tumor. Methods include:

Matched buffy coat sequencing: Direct comparison of cfDNA variants against white blood cell DNA
Population databases: Filtering against known CHIP-associated genes like DNMT3A, TET2, and ASXL1
VAF trajectory analysis: CHIP variants typically maintain stable VAF, unlike tumor-derived ctDNA

About the author

Prasad Kumkar

CEO & MD, Inference Systems

Prasad Kumkar is the CEO & MD of Inference Systems and writes about AI systems architecture, LLM infrastructure, model serving, evaluation, and production deployment. Over 5+ years, he has worked across computer vision models, L5 autonomous vehicle systems, and LLM research, with a focus on taking complex AI ideas into real-world engineering systems.

His work and writing cover AI systems, large language models, AI agents, multimodal systems, autonomous systems, inference optimization, RAG, evaluation, and production AI engineering.

Limited slotsGet a Free AI Consultation

How We Work

Custom AI workflows for your Business

One-fit-all AI don't work for modern businesses. At Inferensys, we aim to understand your business & custom requirements; which we use to define most efficient agentic workflows, the data, and the tools for your business.